title: [Lipid formulations of amphotericin].
abstract: Amphotericin B deoxycholate use has increased during the past years in parallel with the increase in the number of immunosuppressed patients suffering invasive fungal infections. This drug is associated with a high rate of side effects, especially renal toxicity. Lipid formulations (liposomal, lipid complex, colloidal suspension and the Indian liposomal formulation) have been developed, which share the same antifungal spectrum but differ in efficacy and toxicity. A review of amphotericin lipid formulations is presented, focusing on differences in efficacy and, especially renal toxicity. The main problem for use of these formulations in Latin America is their highcost.
authors.forename: Martha C
authors.initials: MC
authors.lastname: Botero
authors.forename: Marcela
authors.initials: M
authors.lastname: Puentes-Herrera
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Cortés
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects / Q000737:chemistry*; D000935:Antifungal Agents / Q000009:adverse effects / Q000737:chemistry*; D003102:Colloids; D005079:Excipients; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes; D009181:Mycoses / Q000188:drug therapy
chemical_list: D000935:Antifungal Agents; D003102:Colloids; D005079:Excipients; D008055:Lipids; D008081:Liposomes; D000666:Amphotericin B